IPCA Laboratories

IPCA Laboratories ROIC

The Return on Invested Capital (ROIC) of IPCA Laboratories (IPCALAB.NS) as of Nov 1, 2026 is 13.96 %. In the previous year, Return on Invested Capital (ROIC) was 9.18 % — a change of 52.13% (higher).

ROIC

13.96 %

YoY

52.13%

Last updated:

Return on Invested Capital (ROIC) of IPCA Laboratories is 2026 13.96 % . Return on Invested Capital (ROIC) of IPCA Laboratories was 2025 9.18 % . It decreases by 52.13% higher compared to the previous year.

The IPCA Laboratories ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2019
12.81 INR
Jan 1, 2020
14.95 INR
Jan 1, 2021
23.29 INR
Jan 1, 2022
14.17 INR
Jan 1, 2023
6.57 INR
Jan 1, 2024
7.29 INR
Jan 1, 2025
9.18 INR
Jan 1, 2026
13.96 INR
The IPCA Laboratories ROIC history
YEARROICYoY
13.96 %+52.13%
9.18 %+25.95%
7.29 %+10.89%
6.57 %-53.63%
14.17 %-39.15%
23.29 %+55.71%
14.95 %+16.75%
12.81 %+69.14%
7.57 %+16.17%
6.52 %+104.95%
3.18 %-54.38%
6.97 %-58.39%
16.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Return on Invested Capital (ROIC) of IPCA Laboratories is 13.96 % in 2026.

Return on Invested Capital (ROIC) of IPCA Laboratories changed from 9.18 % to 13.96 %, representing a 52.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IPCA Laboratories

All Key Metrics — IPCA Laboratories